Vasculitis & polymyalgia rheumatica

Myeloperoxidase–anti-neutrophil cytoplasmic antibody positivity and disease characteristics, treatment, and prognosis in eosinophilic granulomatosis with polyangiitis

Scand J RheumatolPublished Retrospective cohort study

Authors' conclusion

Patients with MPO-ANCA-positive EGPA demonstrated different baseline clinical characteristics from MPO-ANCA-negative patients. However, subsequent relapses and serious infectious diseases were comparable.

Study context

Population
Patients with new-onset or severely relapsing eosinophilic granulomatosis with polyangiitis (EGPA) enrolled in the J-CANVAS registry; PR3-ANCA-positive patients excludednew onset 159
Participants
166 patients
Exposure
MPO-ANCA-positive vs MPO-ANCA-negative EGPA
  • MPO-ANCA positiven = 62
  • MPO-ANCA negativen = 104reference
Methodological detailsregistry-based (J-CANVAS)
  • Registry-based (J-CANVAS)

Main finding

As reported in the abstract

  • MPO-ANCA positive had significantly more frequent mucous membrane and eye involvement, more frequent renal involvement, higher total BVAS, higher neutrophil counts and higher CRP at baseline
  • No differences in age or sex between groups
  • Incidence rates of severe relapse and minor relapse comparable; MPO-ANCA positivity not a significant factor in relapse (Cox regression)

Observational data: associations, not effects.

Further findings

Treatment

RTX administered more frequently in MPO-ANCA positive; no other differences in treatment

eGFR and prednisolone doses · weeks 24 and 48

Comparable in both groups

Safety

Serious infectious diseases

Incidence rates comparable; MPO-ANCA positivity not a significant factor (Cox regression)

Original publication

Myeloperoxidase–anti-neutrophil cytoplasmic antibody positivity and disease characteristics, treatment, and prognosis in eosinophilic granulomatosis with polyangiitis. Scand J Rheumatol. Published 4 November 2025. doi:10.1080/03009742.2025.2572885

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.